In alpha‐1‐antitrypsin (α1AT)‐deficient models, autophagy agonists such as rapamycin reduce mutant α1AT aggregate burden in the liver by enhancing autophagic clearance, thereby attenuating hepatic fibrosis [22]. This evidence concerns the gene SERPINA1 and Hepatic fibrosis.